

P33099USw

In the Claims:

Please cancel pending claims 1-23, and replace as follows:

1. -23. (Canceled).
24. (New) 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydropyran-4-ylmethyl)-amide or a pharmaceutically acceptable salt or solvate thereof.
25. (New) The compound as claimed in claim 24 in nanoparticulate form.
26. (New) 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydropyran-4-ylmethyl)-amide.
27. (New) The compound as claimed in claim 26 in nanoparticulate form.
28. (New) A pharmaceutical composition comprising 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydropyran-4-ylmethyl)-amide or a pharmaceutically acceptable salt or solvate thereof.
29. (New) The pharmaceutical composition as claimed in claim 28 further comprising a pharmaceutical carrier or diluent thereof.
30. (New) The pharmaceutical composition as claimed in claim 29 further comprising a second therapeutic agent.
31. (New) The pharmaceutical composition as claimed in claim 28 wherein the compound is in nanoparticulate form.
32. (New) The pharmaceutical composition as claimed in claim 31 further comprising a pharmaceutical carrier or diluent thereof.

P33099USw

33. (New) A pharmaceutical composition comprising 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydropyran-4-ylmethyl)-amide.
34. (New) The pharmaceutical composition as claimed in claim 33 further comprising a pharmaceutical carrier or diluent thereof.
35. (New) The pharmaceutical composition as claimed in claim 34 further comprising a second therapeutic agent.
36. (New) The pharmaceutical composition as claimed in claim 33 wherein the compound is in nanoparticulate form.
37. (New) The pharmaceutical composition as claimed in claim 36 further comprising a pharmaceutical carrier or diluent thereof.
38. (New) The pharmaceutical composition as claimed in claim 37 further comprising a second therapeutic agent.
39. (New) A method of treating a human or animal subject suffering from a condition selected from an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis, which comprises administering to said subject a therapeutically effective amount of 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydropyran-4-ylmethyl)-amide or a pharmaceutically acceptable salt or solvate thereof.
40. (New) The method claimed claim 39 wherein the condition is pain selected from inflammatory pain, visceral pain, cancer pain, neuropathic pain, lower back pain, muscular skeletal, post operative pain, acute pain and migraine.

P33099USw

41. (New) The method as claimed claim 39 wherein the condition is an inflammatory disorder selected from Crohn's disease, ulcerative colitis or inflammatory bowel disease.
42. (New) A method of treating a human or animal subject suffering from a condition selected from an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis, which comprises administering to said subject a therapeutically effective amount of 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydropyran-4-ylmethyl)-amide.
43. (New) The method claimed claim 42 wherein the condition is pain selected from inflammatory pain, visceral pain, cancer pain, neuropathic pain, lower back pain, muscular skeletal, post operative pain, acute pain and migraine.
44. (New) The method as claimed claim 42 wherein the condition is an inflammatory disorder selected from Crohn's disease, ulcerative colitis or inflammatory bowel disease.